SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

March 31, 2026

Study Completion Date

June 15, 2027

Conditions
Covid19Hypoxic Respiratory Failure
Interventions
DRUG

Isoflurane Inhalant Product

Isoflurane will be administered using an inhalation device

DRUG

Sevoflurane inhalant product

Sevoflurane will be administered using an inhalation device

Trial Locations (13)

T6G 2B7

University of Alberta Hospital, Edmonton

T6L 5X8

Grey Nuns Community Hospital, Edmonton

N6A 5A5

London Health Sciences Centre - University Hospital, London

Unknown

London Health Sciences Centre - Victoria Hospital, London

The Ottawa Hospital, Ottawa

M4N3M5

Sunnybrook Health Sciences Centre, Toronto

M5G 2C4

University Health Network - Toronto General Hospital, Toronto

M5T 2S8

University Health Network - Toronto Western Hopsital, Toronto

H2X 3E4

Centre Hospitalier de l'Université de Montréal, Montreal

H4A 3J1

McGill University Health Centre - Royal Victoria Hospital, Montreal

H4J1C5

Hôpital Sacré-Coeur de Montréal, Montreal

G1V 4G5

Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ), Québec

J1K 2R1

Universite de Sherbrooke, Sherbrooke

All Listed Sponsors
lead

Sunnybrook Health Sciences Centre

OTHER

NCT04415060 - SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival | Biotech Hunter | Biotech Hunter